Celltrion R&D Headquarters Kwon Ki-seong mentions at the National Assembly debate
“After the results of phase 2 clinical trials are revealed, overseas expansion will be activated”
![The photo shows the Celltrion antibody treatment that was released to the media on December 22, 2020. [연합뉴스 자료사진] photo@yna.co.kr](https://i0.wp.com/img5.yna.co.kr/photo/yna/YH/2020/12/29/PYH2020122916120001300_P4.jpg?w=560&ssl=1)
The photo shows the Celltrion antibody treatment that was released to the media on December 22, 2020. [연합뉴스 자료사진] [email protected]
(Seoul = Yonhap News) Reporter Kim Jandi Gye Seung-Hyun = Celltrion is an existing antibody against the antibody treatment “Reekyronaju” (ingredient name legdanvimab code name CT-P59) for a novel coronavirus infection (Corona 19), which is about to disclose clinical results. It was revealed on the 12th that it has confirmed the effect of more than a treatment.
Celltrion R&D Director Kwon Ki-seong attended the discussion on’Communication with the Future: The Road to a Clean Country for Corona 19′ co-hosted by Rep. Lee Gwang-jae, Hwang-hee, and Shin Hyun-young on this day. Said.
Lilly and Regeneron’s COVID-19 antibody treatment is a product that has been approved for emergency use by the US Food and Drug Administration (FDA).
Celltrion announced that it is also accelerating its overseas expansion of Rekirona. Celltrion has applied for a conditional permit to the Korean Food and Drug Administration, and at the same time has begun procedures to obtain emergency use approval in the US and Europe.
Headquarters Kwon said, “We are discussing overseas expansion with a specific country.”
Celltrion plans to release data on the results of Phase 2 clinical trials of Rekkirona at the ‘2021 High1 New Drug Development Symposium’, an academic conference hosted by the Korean Pharmacy Society at 6 pm on the 13th.
Unauthorized reproduction-prohibition of redistribution>
2021/01/12 15:17 sent